Epclusa-velpanat (100 mg Velpatasvir / 400 mg Sofosbuvir): Check Drug Details and Specifications

Indication

Epclusa is helpful for treatment of all Hepatitis C adults that are suffering from genotype 1-6 chronic hepatitis C virus.

Note

SIDE EFFECTS :

• Common side effects include muscle pains, headache, nausea, rash, diarrhea, insomnia and cough.
• More severe reactions are connected with allergic reactions to the medications and cardiovascular problems.

INTERACTIONS :

• For the HIV combination Efavirenz / Emtricitabine / Tenofovir, which reduces the area under the curve (AUC) of Velpatasvir by about 50%, and the CYP3A4 and Pgp inducer Rifampicin, which reduces its AUC by about 80%, rendering it likely ineffective.
• Digoxin is eliminated by Pgp; its AUC is increased by about 30% in combination with Velpatasvir and Sofosbuvir.
• Substances that reduce gastric acid, such as Antacids, H2 blockers, and Proton pump inhibitors, reduce Velpatasvir AUC by 20–40%

OVERDOSE :

• Do not use more than prescribed dose.
• If you suspect you may have overdosed, call your healthcare provider.
• Do not take extra dose to make up for the missed dose.

Precaution

• Epclusa is a prescription drug and should be used under proper medical guidance and advice.
• Caution should be exercised in patients with history of stomach problem, liver, kidney, or heart disease during pregnancy and breastfeeding.